Patent · US Active

Azaindazoles as kinase inhibitors and use thereof

US8846673B2 · kind B2 · utility

18Cited by

3References

16Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Jingwu Duan · Yardley, US
Bin Jiang · Norristown, US
Zhonghui Lu · King of Prussia, US

Key dates

Filing date	Aug 11, 2010
Grant date	Sep 30, 2014
Priority date	—
Expiry date	Jun 28, 2031

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P37/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, (I) are useful as kinase modulators, including Btk modulation, wherein A1, A2, A3, R4 are as defined herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.